CytoMed Therapeutics (GDTC) Long-Term Investments (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Long-Term Investments for 5 consecutive years, with $14050.4 as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 91.54% to $14050.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14050.4 through Dec 2025, down 91.54% year-over-year, with the annual reading at $13937.9 for FY2025, 91.38% down from the prior year.
  • Long-Term Investments hit $14050.4 in Q4 2025 for CytoMed Therapeutics, down from $166105.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $201148.6 in Q4 2021 to a low of $14050.4 in Q4 2025.
  • Historically, Long-Term Investments has averaged $139662.6 across 5 years, with a median of $166105.0 in 2024.
  • Biggest five-year swings in Long-Term Investments: increased 14.96% in 2024 and later tumbled 91.54% in 2025.
  • Year by year, Long-Term Investments stood at $201148.6 in 2021, then decreased by 14.23% to $172519.8 in 2022, then fell by 16.25% to $144489.1 in 2023, then rose by 14.96% to $166105.0 in 2024, then crashed by 91.54% to $14050.4 in 2025.
  • Business Quant data shows Long-Term Investments for GDTC at $14050.4 in Q4 2025, $166105.0 in Q4 2024, and $144489.1 in Q4 2023.